Non-orthogonal multiple access (NOMA) is a promising radio access technique for next-generation wireless networks. In this article, we investigate the NOMA-based cooperative relay network. We begin with an introduction of the existing relay-assisted NOMA systems by classifying them into three categories: uplink, downlink, and composite architectures. Then, we discuss their principles and key features, and provide a comprehensive comparison from the perspective of spectral efficiency, energy efficiency, and total transmit power. A novel strategy termed hybrid power allocation is further discussed for the composite architecture, which can reduce the computational complexity and signaling overhead at the expense of marginal sum rate degradation. Finally, major challenges, opportunities, and future research trends for the design of NOMA-based cooperative relay systems with other techniques are also highlighted to provide insights for researchers in this field. Index TermsNon-orthogonal multiple access (NOMA), cooperative relay network, power allocation, degree of asymmetry.

No abstract

No abstract

No abstract

In recent years, with the development of nanomaterials, the research of drug delivery systems has become a new field of cancer therapy. Compared with conventional antitumor drugs, drug delivery systems such as drug nanoparticles (NPs) are expected to have more advantages in antineoplastic effects, including easy preparation, high efficiency, low toxicity, especially active tumor-targeting ability. Drug delivery systems are usually composed of delivery carriers, antitumor drugs, and even target molecules. At present, there are few comprehensive reports on a summary of drug delivery systems applied for tumor therapy. This review introduces the preparation, characteristics, and applications of several common delivery carriers and expounds the antitumor mechanism of different antitumor drugs in delivery carriers in detail which provides a more theoretical basis for clinical application of personalized cancer nanomedicine in the future.